FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals


Journal Website: https://frontlinejournals.org/journals/index.php/fmspj



Research Article

# MOLECULAR STRATIFICATION OF LUNG ADENOCARCINOMA THROUGH GENE EXPRESSION PROFILING

**Submission Date:** September 22, 2024, **Accepted Date:** September 27, 2024,
**Published Date:** October 02, 2024

**Damodaran Reddy**
**Sugen Life Science Private Limited, Tirupati, India**

## ABSTRACT

Lung adenocarcinoma (LUAD), the most common histological subtype of lung cancer, is a highly heterogeneous disease with significant variability in clinical outcomes and responses to treatment. Traditional classifications based on histopathological characteristics have proven insufficient for personalized therapy due to the complexity of molecular alterations within tumors. As precision medicine gains prominence, molecular stratification based on gene expression profiling has emerged as a powerful approach to better classify lung adenocarcinoma, enabling more targeted and effective therapeutic strategies.

Gene expression profiling allows for the identification of specific molecular signatures and genetic alterations that drive the progression and behavior of lung adenocarcinoma. Through high-throughput technologies such as RNA sequencing (RNA-seq) and microarray analysis, large-scale data on gene expression patterns can be generated, providing insights into the biological mechanisms underlying tumor heterogeneity. This molecular information enables stratification of LUAD into distinct subgroups with unique molecular profiles, each associated with specific clinical characteristics, prognosis, and therapeutic

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

sensitivities. Understanding these molecular differences not only improves diagnostic accuracy but also offers the potential to identify novel therapeutic targets and biomarkers for patient selection.

Several molecular subtypes of lung adenocarcinoma have been identified through gene expression profiling, each characterized by distinct genomic alterations and signaling pathway dysregulations. One well-recognized subtype is driven by alterations in the epidermal growth factor receptor (EGFR) gene, which is found in a significant proportion of LUAD patients. EGFR mutations are particularly prevalent in non-smoking populations and are associated with sensitivity to EGFR tyrosine kinase inhibitors (TKIs), making them critical for treatment stratification. Similarly, other subtypes harbor mutations in genes such as KRAS, BRAF, and ALK, each of which has unique therapeutic implications.

In addition to driver mutations, gene expression profiling has identified several immune-related subtypes of lung adenocarcinoma, which differ in their tumor immune microenvironments and responses to immune checkpoint inhibitors (ICIs). Tumors with high expression of immune-related genes, often referred to as "hot" tumors, are characterized by active immune infiltration and are more likely to respond favorably to immunotherapy. Conversely, "cold" tumors, with low immune infiltration, may require combination therapies to enhance immune responsiveness.

A more comprehensive understanding of these subtypes through molecular stratification has significant implications for improving treatment outcomes. For instance, patients with EGFR-mutant or ALK-rearranged tumors benefit greatly from targeted therapies, which can lead to improved progression-free survival. Similarly, immune-related subtypes can guide the use of immunotherapy, ensuring that only patients most likely to benefit from these treatments receive them, while sparing others from potential toxicity and side effects.

## KEYWORDS

Molecular stratification, lung adenocarcinoma, gene expression profiling, biomarker discovery, personalized medicine, tumor heterogeneity, cancer genomics, transcriptomics, diagnostic biomarkers, therapeutic targets.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

## INTRODUCTION

Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with lung adenocarcinoma (LUAD) representing a significant subset of this disease. As the most prevalent type of non-small cell lung cancer (NSCLC), LUAD is characterized by its heterogeneity in clinical behavior, histopathological features, and molecular alterations. Traditionally, lung adenocarcinoma was classified based on histological criteria; however, the advent of molecular biology and the rise of precision medicine have shifted the focus toward understanding the underlying genetic and molecular mechanisms driving tumorigenesis. Gene expression profiling has emerged as a powerful tool for unraveling the complexities of LUAD, enabling the stratification of patients based on distinct molecular characteristics that influence prognosis, treatment response, and overall survival.

Molecular stratification refers to the categorization of tumors based on specific genetic, epigenetic, or proteomic profiles. In lung adenocarcinoma, this approach allows for a more precise understanding of tumor biology, helping clinicians identify subgroups of patients who may benefit from targeted therapies or immunotherapies. The recognition of molecular heterogeneity within LUAD has significant implications for treatment strategies, as conventional therapies may not be equally effective across all patient subpopulations. For instance, specific genetic alterations, such as mutations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) rearrangements, and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, have been linked to distinct clinical outcomes and responses to targeted therapies. Therefore, the ability to stratify patients based on these molecular markers is crucial for optimizing treatment and improving patient outcomes.

Gene expression profiling involves analyzing the expression levels of thousands of genes simultaneously to characterize the molecular landscape of tumors. Various techniques have been developed for this purpose, including microarray analysis and RNA sequencing (RNA-seq). Microarray technology, which measures the expression of predefined sets of genes, has been

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

widely used to identify gene signatures associated with prognosis and treatment response in lung adenocarcinoma. RNA-seq, on the other hand, provides a more comprehensive view of the transcriptome, allowing for the detection of novel transcripts, alternative splicing events, and non-coding RNAs, thereby offering deeper insights into the molecular mechanisms underpinning LUAD.

The application of gene expression profiling in LUAD has led to the identification of several molecular subtypes, each associated with distinct clinical features. For example, studies have identified subgroups characterized by specific gene expression signatures related to epithelial-mesenchymal transition (EMT), immune response, and metabolic pathways. These findings highlight the potential of gene expression profiling not only for diagnosis and prognosis but also for predicting treatment response. Moreover, integrating gene expression data with clinical parameters and other omics data (e.g., genomics, proteomics) can further enhance the stratification of LUAD patients, paving the way for personalized treatment approaches.

Despite the advances in gene expression profiling, several challenges remain in the molecular stratification of lung adenocarcinoma. One major challenge is the biological variability among patients, which can be influenced by factors such as tumor microenvironment, treatment history, and individual genetic backgrounds. Additionally, the complexity of tumor heterogeneity, where different regions of the same tumor may exhibit distinct molecular characteristics, complicates the interpretation of gene expression data. Standardization of sample collection, processing, and data analysis is essential to ensure the reproducibility and clinical applicability of gene expression-based stratification methods.

## METHOD

Lung adenocarcinoma, a predominant subtype of non-small cell lung cancer (NSCLC), exhibits significant heterogeneity at the molecular level, necessitating robust methodologies for stratifying patients based on gene expression profiles. This stratification can lead to personalized treatment approaches and improved patient outcomes. The methodologies employed for molecular stratification can be broadly categorized into sample collection, gene expression analysis, bioinformatics processing, and validation techniques.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Publisher: Frontline Journals

1. Sample Collection and Preparation

The initial step in molecular stratification involves the collection of appropriate tissue samples. Samples can be obtained through surgical resections, biopsies, or liquid biopsies (e.g., circulating tumor cells or cell-free DNA). Following collection, several critical steps are performed:

Tissue Processing: Collected tissue samples are processed to preserve RNA integrity. This typically involves immediate freezing in liquid nitrogen or stabilization using RNAlater solutions to prevent RNA degradation.

Pathological Assessment: Pathological evaluation is essential to confirm the diagnosis of lung adenocarcinoma and to assess tumor characteristics, such as grade and stage. This ensures that only suitable samples are selected for further analysis.

RNA Extraction: Total RNA is extracted from the preserved tissue samples using commercial RNA extraction kits (e.g., TRIzol or column-based methods). The quality and quantity of RNA are assessed using spectrophotometry and electrophoresis (e.g., Agilent Bioanalyzer) to ensure that only high-quality RNA is used for downstream applications.

2. Gene Expression Analysis

The primary focus of molecular stratification lies in the analysis of gene expression profiles. Two predominant techniques are employed for this purpose:

Microarray Analysis: Microarray technology enables the simultaneous measurement of the expression levels of thousands of genes. In this method, complementary DNA (cDNA) synthesized from RNA is labeled and hybridized to a microarray chip containing probes for specific genes. After hybridization, fluorescence signals are detected and quantified, providing a comprehensive gene expression profile.

RNA Sequencing (RNA-Seq): RNA-Seq is a more recent and powerful method that provides a detailed snapshot of the transcriptome. In RNA-Seq, RNA is converted into cDNA, which is then sequenced using next-generation sequencing (NGS) technologies. This approach offers advantages, including the ability to detect novel transcripts, splice variants, and non-coding RNAs, in addition to quantifying gene expression levels. The data generated is extensive, allowing for a

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Publisher: Frontline Journals

more nuanced understanding of the molecular landscape of lung adenocarcinoma.

3. Bioinformatics Processing

Following gene expression analysis, bioinformatics tools are essential for processing and interpreting the vast amounts of data generated:

Data Preprocessing: Raw gene expression data requires preprocessing steps, including quality control (removing low-quality reads), normalization (to account for technical variation), and filtering (to exclude lowly expressed genes). Tools such as the Bioconductor package in R or specific RNA-Seq analysis software (e.g., STAR, DESeq2) are commonly used for this purpose.

Differential Expression Analysis: To identify genes that are significantly differentially expressed between subgroups of lung adenocarcinoma patients (e.g., by stage or response to treatment), statistical methods such as the t-test or analysis of variance (ANOVA) are applied. Results are typically presented in terms of fold changes and p-values, with a false discovery rate (FDR) adjustment to account for multiple testing.

Clustering and Stratification: Bioinformatics tools are employed for clustering patients based on their gene expression profiles. Techniques such as hierarchical clustering, k-means clustering, or machine learning algorithms (e.g., support vector machines) are used to stratify patients into distinct molecular subtypes. This stratification can identify potential biomarkers for prognosis or therapeutic targets.

Pathway and Functional Enrichment Analysis: Further analysis may involve examining the biological pathways and functions associated with differentially expressed genes. Tools such as Gene Ontology (GO) analysis or Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis help elucidate the underlying biological mechanisms and identify relevant therapeutic targets.

4. Validation Techniques

Validation of the findings is crucial for confirming the robustness and clinical relevance of the stratification approach:

Independent Cohorts: The initial stratification results should be validated using independent patient cohorts or datasets. This step ensures that the identified gene expression patterns are

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

reproducible and applicable across different populations.

Quantitative Real-Time PCR (qRT-PCR): Selected genes of interest may be validated using qRT-PCR, a technique that quantitatively assesses gene expression levels in a smaller number of samples. This method confirms the differential expression findings from microarray or RNA-Seq analyses.

Survival Analysis: The clinical relevance of the stratification is further assessed through survival analysis, where patient outcomes (e.g., overall survival, progression-free survival) are correlated with the identified molecular subtypes. Kaplan-Meier survival curves and Cox proportional hazards models are commonly used to evaluate the prognostic significance of gene expression-based stratification.

## Results

The molecular stratification of lung adenocarcinoma using gene expression profiling has yielded significant insights into the biological heterogeneity of the disease. This stratification has allowed for the identification of distinct molecular subtypes, each characterized by unique genetic and clinical features, which has important implications for personalized treatment approaches and prognosis.

Identification of Molecular Subtypes

Gene expression profiling of lung adenocarcinoma samples revealed the existence of several molecular subtypes that correspond to specific genetic alterations and pathways. These subtypes include:

EGFR-Mutant Subtype: One of the most prevalent molecular subtypes identified is characterized by mutations in the Epidermal Growth Factor Receptor (EGFR) gene. This subtype is commonly associated with non-smokers or light smokers and tends to respond well to EGFR tyrosine kinase inhibitors (TKIs). The gene expression profile of this subtype shows upregulation of pathways related to cell proliferation and survival, which are driven by aberrant EGFR signaling.

KRAS-Mutant Subtype: Another prominent subtype is defined by mutations in the KRAS gene. Unlike the EGFR-mutant subtype, patients with KRAS mutations often do not respond well to TKIs, and therapeutic options are more limited. The gene expression patterns in this subtype are associated with pathways involving

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Publisher: Frontline Journals

inflammation, immune evasion, and cell cycle dysregulation. This finding highlights the aggressive nature of KRAS-driven lung adenocarcinomas and suggests a potential role for targeting inflammatory pathways in future treatments.

ALK Rearrangement Subtype: Rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene were identified as a distinct molecular subtype. ALK-positive lung adenocarcinoma is characterized by a specific gene fusion, which leads to the activation of downstream signaling pathways related to cell growth and differentiation. Gene expression analysis revealed an upregulation of cell adhesion and migration-related genes, which may explain the metastatic potential often observed in this subtype. Targeted therapies, such as ALK inhibitors, have shown promising results for this group.

Immune-Related Subtype: One of the more recently identified subtypes involves tumors with high expression of immune-related genes, particularly those associated with the programmed death-ligand 1 (PD-L1) pathway. This subtype tends to have a high tumor mutation burden (TMB) and responds well to immune checkpoint inhibitors, such as anti-PD-1 or anti-PD-L1 therapies. The gene expression profile of this subtype shows enrichment in immune cell signaling, cytokine production, and T-cell receptor pathways, suggesting that the immune microenvironment plays a critical role in tumor progression and response to immunotherapy.

Prognostic Implications

The molecular stratification of lung adenocarcinoma based on gene expression profiling has profound implications for patient prognosis. Each molecular subtype not only presents distinct genetic and molecular characteristics but also exhibits unique clinical behaviors:

EGFR-Mutant Subtype: Patients with EGFR mutations generally have a better prognosis due to the availability of targeted therapies that specifically inhibit EGFR activity. These patients often experience prolonged progression-free survival when treated with TKIs.

KRAS-Mutant Subtype: In contrast, patients with KRAS mutations typically face poorer outcomes due to the lack of effective targeted therapies and the aggressive nature of the disease. However,

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

ongoing research into novel inhibitors targeting KRAS is showing promise.

ALK Rearrangement Subtype: Similar to the EGFR-mutant subtype, patients with ALK rearrangements benefit from ALK inhibitors, leading to improved survival rates. However, resistance to ALK inhibitors can develop over time, necessitating further investigation into combination therapies.

Immune-Related Subtype: Patients with tumors characterized by high immune activity and PD-L1 expression tend to have favorable responses to immunotherapy, often resulting in long-term remission. The identification of this subtype emphasizes the importance of incorporating immune checkpoint inhibitors into treatment strategies for suitable patients.

## Discussion

Lung adenocarcinoma (LUAD) is a subtype of non-small cell lung cancer (NSCLC) that has become increasingly prevalent worldwide, largely due to the rise in smoking-related diseases and environmental factors. Despite advancements in diagnostic and therapeutic strategies, LUAD remains a major cause of cancer-related mortality. Traditional classification methods often fail to capture the molecular heterogeneity of this disease, highlighting the need for more nuanced approaches. Gene expression profiling (GEP) has emerged as a powerful tool for the molecular stratification of lung adenocarcinoma, enabling better understanding of the disease mechanisms and potential therapeutic targets.

Gene expression profiling involves measuring the activity (expression) levels of thousands of genes simultaneously to obtain an overview of cellular function. This technique provides insights into the molecular underpinnings of diseases like LUAD by identifying specific gene expression patterns associated with different clinical outcomes, tumor behavior, and responses to therapy. High-throughput technologies, such as microarrays and RNA sequencing (RNA-seq), have revolutionized the field by allowing comprehensive analysis of gene expression at an unprecedented scale.

In the context of LUAD, GEP can reveal distinct molecular subtypes characterized by specific gene signatures. For instance, studies have identified subgroups within LUAD that correlate with variations in prognosis and treatment

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

response. By stratifying patients based on these gene expression profiles, clinicians can better predict disease progression and tailor treatment strategies to individual patients.

The clinical implications of molecular stratification using gene expression profiling are profound. One of the primary benefits is the potential for personalized medicine, wherein treatment approaches are customized based on the molecular characteristics of a patient's tumor. For example, certain gene expression signatures may indicate sensitivity or resistance to specific therapies, such as targeted treatments or immunotherapies. This stratification can lead to improved treatment efficacy, reduced side effects, and better overall patient outcomes.

Additionally, gene expression profiling can aid in the identification of novel therapeutic targets. By elucidating the pathways and biological processes that are altered in various LUAD subtypes, researchers can pinpoint new targets for drug development. For instance, the identification of specific oncogenes or tumor suppressor genes that are differentially expressed in aggressive forms of LUAD could pave the way for the development of targeted therapies aimed at these alterations. This approach has already yielded promising results with drugs designed to inhibit specific mutations, such as EGFR and ALK, which are commonly found in LUAD.

Despite the advantages of gene expression profiling for molecular stratification, several challenges and limitations remain. One significant issue is the complexity of the data generated, which requires sophisticated analytical techniques to interpret. The inherent heterogeneity of tumors can also complicate the identification of consistent gene expression patterns, leading to variability in results. As such, establishing standardized protocols for sample collection, processing, and analysis is crucial to ensure reproducibility and comparability of findings across studies.

## Conclusion

Molecular stratification of lung adenocarcinoma through gene expression profiling represents a significant advancement in our understanding of this complex disease. By elucidating the molecular subtypes of LUAD, GEP not only enhances our ability to predict clinical outcomes but also opens avenues for personalized treatment and the development of novel

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

therapeutic targets. While challenges remain in terms of data interpretation and clinical integration, ongoing research and technological advancements hold the promise of transforming lung cancer care, ultimately leading to improved patient outcomes and survival rates. As the field progresses, continued collaboration among researchers, clinicians, and regulatory bodies will be essential to translate these insights into clinical practice effectively.

## REFERENCES

1. Beer D G, Kardia S L, Huang C-C, GiordanoT J, Levin A M, Misek D E and Thomas D G(2002), "Gene-Expression Profiles PredictSurvival of Patients with LungAdenocarcinoma",Nature Medicine, Vol. 8,No. 8, pp. 816-824.
2. Bhattacharjee A, Richards W G, Staunton J,Li C, Monti S, Vasa P and Gillette M (2001),"Classification of Human Lung Carcinomasby mRNA Expression Profiling RevealsDistinct Adenocarcinoma Subclasses",Proceedings of the National Academy ofSciences, Vol. 98, No. 24, pp. 13790-13795.
3. Eldridge L (2015), "Lung AdenocarcinomaSymptoms, Treatments, and Prognosis", from http://lungcancer.about.com/od/typesoflungcancer/a/Lung-Adenocarcinoma.htm
4. Etzioni R, Urban N, Ramsey S, McIntosh M,Schwartz S, Reid B and Hartwell L (2003),"The Case for Early Detection",NatureReviews Cancer, Vol. 3, No. 4, pp.243-252.
5. Fridman J S and Lowe S W (2003), "Controlof Apoptosis by p53",Oncogene, Vol. 22,No. 56, pp. 9030-9040.
6. Garber M E, Troyanskaya O G, Schluens K,Petersen S, Thaesler Z, Pacyna-GengelbachM and Whyte R I (2001), "Diversity of GeneExpression in Adenocarcinoma of the Lung",Proceedings of the National Academy ofSciences, Vol. 98, No. 24, pp. 13784-13789.
7. Hayes D F, Bast R C, Desch C E, FritscheH, Kemeny N E, Jessup J M and Norton L(1996), "Tumor Marker Utility GradingSystem: A Framework to Evaluate ClinicalUtility of Tumor Markers",Journal of theNational Cancer Institute, Vol. 88, No. 20,pp. 1456-1466.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 10 Pages: 11-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

8. Hayes D N, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A and MeyersonM (2006), "Gene Expression ProfilingReveals Reproducible Human Lung gAdenocarcinoma Subtypes in MultipleIndependent Patient Cohorts",Journal ofClinical Oncology, Vol. 24, No. 31 ,pp. 5079-5090.
9. Levy M A, Lovly C M and Pao W (2012),"Translating Genomic Information intoClinical Medicine: Lung Cancer as aParadigm",Genome Research, Vol. 22,No. 11, pp. 2101-2108.
10. Network C G A R (2014), "ComprehensiveMolecular Profiling of LungAdenocarcinoma",Nature, Vol. 511,No. 7511, pp. 543-550.
11. Ritchie M E, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth G K (2015), "LimmaPowers Differential Expression Analyses forRNA-Sequencing and Microarray Studies",Nucleic. Acids Res., gkv007.
12. Rousseeuw P J (1987), "Silhouettes: AGraphical Aid to the Interpretation andValidation of Cluster Analysis",Journal ofComputational and Applied Mathematics,Vol. 20, pp. 53-65.
13. Siegel R, Ma J, Zou Z and Jemal A (2014),"Cancer Statistics",A Cancer Journal forClinicians, Vol. 64, No. 1, pp. 9-29.
14. Takeuchi T, Tomida S, Yatabe Y, Kosaka T,Osada H, Yanagisawa K and Takahashi T(2006), "Expression Profile –Defined Classification of Lung AdenocarcinomaShows Close Relationship with UnderlyingMajor Genetic Changes andClinicopathologic Behaviors",Journal ofClinical Oncology, Vol. 24, No. 11 ,pp. 1679-1688.
15. Wilkerson M D, Yin X, Walter V, Zhao N,Cabanski C R, Hayward M C and Thorne LB (2012), "Differential Pathogenesis of LungAdenocarcinoma Subtypes InvolvingSequence Mutations, Copy Number,Chromosomal Instability, and Methylation",PLoS ONE, Vol. 7, No. 5, p. e36530.